Meeting
2022 ASCO Annual Meeting
Phase 2 trial of bavituximab with chemoradiation and adjuvant temozolomide in newly diagnosed glioblastoma.
Authors
Ina Ly
Massachusetts General Hospital, Boston, MA
Ina Ly , Leland Richardson , Mofei Liu , Alona Muzikansky , Kevin Lou , David A. Reardon , Isabel Arrillaga-Romany , Deborah Anne Forst , Justin T. Jordan , Eudocia Quant Lee , Jorg Dietrich , Lakshmi Nayak , Patrick Y. Wen , Ugonma Nnenna Chukwueke , Anita Giobbie-Hurder , Bryan D. Choi , Tracy Batchelor , Jayashree Kalpathy-Cramer , William T. Curry , Elizabeth R. Gerstner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT03139916
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2030)
DOI
10.1200/JCO.2022.40.16_suppl.2030
Abstract #
2030
Poster Bd #
368
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
MRI changes in patients with newly diagnosed glioblastoma treated as part of a phase II trial with bavituximab, radiation, and temozolomide.
First Author: Ina Ly
Poster
2019 ASCO Annual Meeting
Health-related quality of life (HRQL) in VERTU: A randomized phase II trial of veliparib (V), radiotherapy (RT), and temozolomide (TMZ) for newly diagnosed MGMT unmethylated (uMGMT) glioblastoma (GBM).
First Author: Hao-Wen Sim
Poster
2014 ASCO Annual Meeting
Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902).
First Author: Evanthia Galanis
Poster
2014 ASCO Annual Meeting
Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma.
First Author: Abdullah Khalaf Altwairgi